Immunoglobulin G1 Anti-(Human Cd33 (Antigen)) (Human-Mouse Monoclonal Hum195 .Gamma.1-Chain), Disulfide With Human Monoclonal Hum195 .Kappa.-Chain, Dimer
Leukemia
Explore 124 assets in Leukemia →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Jonsson Comprehensive Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00006084CT.gov Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia | — | Unknown | — | — | — |
NCT00016159CT.gov Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia | — | Completed | — | — | — |
NCT00006045CT.gov Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia | — | Unknown | — | — | — |
NCT00002890CT.gov Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | — | Completed | — | — | — |
NCT00002800CT.gov Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT00002609CT.gov Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1 Anti-(Human Cd33 (Antigen)) (Human-Mouse Monoclonal Hum195 .Gamma.1-Chain), Disulfide With Human Monoclonal Hum195 .Kappa.-Chain, Dimer (this asset) | Jonsson Comprehensive Cancer Center | P3 | B · 60 |
| Vincristine Sulfate | Inhye Ahn | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BB |
| Mercaptopurine Anhydrous | Dana-Farber Cancer Institute | P3 | BB |
| Busulfanum | National Cancer Institute (NCI) | P4 | BB |
| Daunomycin | Richard Stone, MD | P3 | BB |
| Asparaginase | Gruppo Italiano Malattie EMatologiche dell'Adulto | P3 | BB |
| Pegaspargase | Dana-Farber Cancer Institute | P3 | BB |
| Idarubicin | Affiliated Hospital of Nantong University | P3 | BB |
+42 more in the Leukemia cohort
Other indications for Immunoglobulin G1 Anti-(Human Cd33 (Antigen)) (Human-Mouse Monoclonal Hum195 .Gamma.1-Chain), Disulfide With Human Monoclonal Hum195 .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P2 | B · 60 |
| Neutropenia | — | P2 | B · 57 |
| Myelodysplastic Syndrome | — | P2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1 Anti-(Human Cd33 (Antigen)) (Human-Mouse Monoclonal Hum195 .Gamma.1-Chain), Disulfide With Human Monoclonal Hum195 .Kappa.-Chain, Dimer in Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-cd33-antigen-human-mouse-monoclonal-hum195-gamma1-chain-disulfide-with-human-monoclonal-hum195-kappa-chain-dimer-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →